Proposed Strategies for Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukaemia

English version

Vyšlo v časopise: Klin Onkol 2019; 32(4): 313
Kategorie: Dopis redakci

Zdroje

1. Koca E, Haznedaroðlu ÝC. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Hematol 2005; 22 (4): 161–172.

2. Rychter A, Jerzmanowski P, Hołub A et al. Treatment adherence in chronic myeloid leukaemia patients receiving tyrosine kinase inhibitors. Med Oncol 2017; 34 (6): 104. doi: 10.1007/s12032-017-0958-6.

3. Alrabiah Z, Alhossan A, Yun S et al. Adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia: meta-analyses of prevalence rates by measurement method. Blood 2016; 128 (22): 3610.

4. Al-Dewik NI, Morsi HM, Samara MM et al. Is adherence to imatinib mesylate treatment among patients with chronic myeloid leukemia associated with better clinical outcomes in Qatar? Clin Med Insights Oncol 2016; 10: 95–104. doi: 10.4137/CMO.S32822.

5. Ganesan P, Sagar TG, Dubashi B et al. Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 2011; 86 (6): 471–474. doi: 10.1002/ajh.22019.

6. Ibrahim AR, Eliasson L, Apperley JF et al. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term the-rapy. Blood 2011; 117 (14): 3733–3736. doi: 10.1182/blood-2010-10-309807.

7. Marin D, Bazeos A, Mahon FX et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28 (14): 2381–2388. doi: 10.1200/JCO.2009.26.3087.

8. Hall AE, Paul C, Bryant J et al. To adhere or not to adhere: rates and reasons of medication adherence in hematological cancer patients. Crit Rev Oncol Hematol 2016; 97: 247–262. doi: 10.1016/j.critrevonc.2015.08.025.

9. Al-Barrak J, Cheung WY. Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia. Support Care Cancer 2013; 21 (8): 2351–2357. doi: 10.1007/s00520-013-1831-6.